Olanzapine Teva

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
25-09-2023
产品特点 产品特点 (SPC)
25-09-2023
公众评估报告 公众评估报告 (PAR)
01-03-2013

有效成分:

olanzapine

可用日期:

Teva B.V. 

ATC代码:

N05AH03

INN(国际名称):

olanzapine

治疗组:

Psycholeptics

治疗领域:

Schizophrenia; Bipolar Disorder

疗效迹象:

AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

產品總結:

Revision: 30

授权状态:

Authorised

授权日期:

2007-12-12

资料单张

                                82
B. PACKAGE LEAFLET
83
PACKAGE LEAFLET: INFORMATION FOR THE USER
OLANZAPINE TEVA 2.5 MG FILM-COATED TABLETS
OLANZAPINE TEVA 5 MG FILM-COATED TABLETS
OLANZAPINE TEVA 7.5 MG FILM-COATED TABLETS
OLANZAPINE TEVA 10 MG FILM-COATED TABLETS
OLANZAPINE TEVA 15 MG FILM-COATED TABLETS
OLANZAPINE TEVA 20 MG FILM-COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Olanzapine Teva is and what it is used for
2.
What you need to know before you take Olanzapine Teva
3.
How to take Olanzapine Teva
4.
Possible side effects
5.
How to store Olanzapine Teva
6.
Contents of the pack and other information
1.
WHAT OLANZAPINE TEVA IS AND WHAT IT IS USED FOR
Olanzapine Teva contains the active substance olanzapine. Olanzapine
Teva belongs to a group of
medicines called antipsychotics and is used to treat the following
conditions:
-
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
-
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
Olanzapine Teva has been shown to prevent recurrence of these symptoms
in patients with bipolar
disorder whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE OLANZAPINE TEVA
_ _
DO NOT TAKE OLANZAPINE TEVA
-
if you are allergic to olanzapine or any of the other ingredients of
this medicine (listed in sect
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Olanzapine Teva 2.5 mg film-coated tablets
Olanzapine Teva 5 mg film-coated tablets
Olanzapine Teva 7.5 mg film-coated tablets
Olanzapine Teva 10 mg film-coated tablets
Olanzapine Teva 15 mg film-coated tablets
Olanzapine Teva 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Olanzapine Teva 2.5 mg film-coated tablets
Each film-coated tablet contains 2.5 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 71.3 mg lactose.
Olanzapine Teva 5 mg film-coated tablets
Each film-coated tablet contains 5 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 68.9 mg lactose.
Olanzapine Teva 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 103.3 mg lactose.
Olanzapine Teva 10 mg film-coated tablets
Each film-coated tablet contains 10 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 137.8 mg lactose.
Olanzapine Teva 15 mg film-coated tablets
Each film-coated tablet contains 15 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 206.7 mg lactose.
Olanzapine Teva 20 mg film-coated tablets
Each film-coated tablet contains 20 mg olanzapine.
_Excipient with known effect _
Each film-coated tablet contains 275.5 mg lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Olanzapine Teva 2.5 mg film-coated tablets
White, biconvex, round film-coated tablets, debossed ”OL 2.5” on
one side and plain on the other.
Olanzapine Teva 5 mg film-coated tablets
White, biconvex, round film-coated tablets, debossed ”OL 5” on one
side and plain on the other.
Olanzapine Teva 7.5 mg film-coated tablets
White, biconvex, round film-coated tablets, debossed ”OL 7.5” on
one side and plain on the other.
3
Olanzapine Teva 10 mg film-coated tablets
White, biconvex, round film-coated tablets, debossed 
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 25-09-2023
产品特点 产品特点 保加利亚文 25-09-2023
公众评估报告 公众评估报告 保加利亚文 01-03-2013
资料单张 资料单张 西班牙文 25-09-2023
产品特点 产品特点 西班牙文 25-09-2023
公众评估报告 公众评估报告 西班牙文 01-03-2013
资料单张 资料单张 捷克文 25-09-2023
产品特点 产品特点 捷克文 25-09-2023
公众评估报告 公众评估报告 捷克文 01-03-2013
资料单张 资料单张 丹麦文 25-09-2023
产品特点 产品特点 丹麦文 25-09-2023
公众评估报告 公众评估报告 丹麦文 01-03-2013
资料单张 资料单张 德文 25-09-2023
产品特点 产品特点 德文 25-09-2023
公众评估报告 公众评估报告 德文 01-03-2013
资料单张 资料单张 爱沙尼亚文 25-09-2023
产品特点 产品特点 爱沙尼亚文 25-09-2023
公众评估报告 公众评估报告 爱沙尼亚文 01-03-2013
资料单张 资料单张 希腊文 25-09-2023
产品特点 产品特点 希腊文 25-09-2023
公众评估报告 公众评估报告 希腊文 01-03-2013
资料单张 资料单张 法文 25-09-2023
产品特点 产品特点 法文 25-09-2023
公众评估报告 公众评估报告 法文 01-03-2013
资料单张 资料单张 意大利文 25-09-2023
产品特点 产品特点 意大利文 25-09-2023
公众评估报告 公众评估报告 意大利文 01-03-2013
资料单张 资料单张 拉脱维亚文 25-09-2023
产品特点 产品特点 拉脱维亚文 25-09-2023
公众评估报告 公众评估报告 拉脱维亚文 01-03-2013
资料单张 资料单张 立陶宛文 25-09-2023
产品特点 产品特点 立陶宛文 25-09-2023
公众评估报告 公众评估报告 立陶宛文 01-03-2013
资料单张 资料单张 匈牙利文 25-09-2023
产品特点 产品特点 匈牙利文 25-09-2023
公众评估报告 公众评估报告 匈牙利文 01-03-2013
资料单张 资料单张 马耳他文 25-09-2023
产品特点 产品特点 马耳他文 25-09-2023
公众评估报告 公众评估报告 马耳他文 01-03-2013
资料单张 资料单张 荷兰文 25-09-2023
产品特点 产品特点 荷兰文 25-09-2023
公众评估报告 公众评估报告 荷兰文 01-03-2013
资料单张 资料单张 波兰文 25-09-2023
产品特点 产品特点 波兰文 25-09-2023
公众评估报告 公众评估报告 波兰文 01-03-2013
资料单张 资料单张 葡萄牙文 25-09-2023
产品特点 产品特点 葡萄牙文 25-09-2023
公众评估报告 公众评估报告 葡萄牙文 01-03-2013
资料单张 资料单张 罗马尼亚文 25-09-2023
产品特点 产品特点 罗马尼亚文 25-09-2023
公众评估报告 公众评估报告 罗马尼亚文 01-03-2013
资料单张 资料单张 斯洛伐克文 25-09-2023
产品特点 产品特点 斯洛伐克文 25-09-2023
公众评估报告 公众评估报告 斯洛伐克文 01-03-2013
资料单张 资料单张 斯洛文尼亚文 25-09-2023
产品特点 产品特点 斯洛文尼亚文 25-09-2023
公众评估报告 公众评估报告 斯洛文尼亚文 01-03-2013
资料单张 资料单张 芬兰文 25-09-2023
产品特点 产品特点 芬兰文 25-09-2023
公众评估报告 公众评估报告 芬兰文 01-03-2013
资料单张 资料单张 瑞典文 25-09-2023
产品特点 产品特点 瑞典文 25-09-2023
公众评估报告 公众评估报告 瑞典文 01-03-2013
资料单张 资料单张 挪威文 25-09-2023
产品特点 产品特点 挪威文 25-09-2023
资料单张 资料单张 冰岛文 25-09-2023
产品特点 产品特点 冰岛文 25-09-2023
资料单张 资料单张 克罗地亚文 25-09-2023
产品特点 产品特点 克罗地亚文 25-09-2023

搜索与此产品相关的警报